Loading MRNA detail
Loading ticker data...
Loading MRNA detail
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S. P. A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Chart data unavailable
In the latest trading session, Moderna (MRNA) closed at $51.3, marking a -1.54% move from the previous day.
In an uncertain market, investors have rushed to get in on these players seen as “safer” investments. They operate in the areas of healthcare and retail, selling treatments and products that are essential -- this offers the potential for revenue stability.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to analysts at Bank of America. They noted that the 2025-2026 vaccine season is winding down, and the company's litigation risks are largely in the past following a $950 million upfront payment in the first quarter, though analysts note the potential for up to $1.3 billion in additional payments depending on the outcome of an ongoing legal appeal.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results,...
This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined.
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026. Moderna's presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," details an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults 50 years and older following prior seasonal influenza vaccination with mRNA-1010 or a licensed egg-based influenza vaccine.
My previous recommendation of Moderna didn't work out so well, because COVID sales have declined over the last several years. Spikevax 2024 sales reached only $3.1B, and RSV sales were a major disappointment at $25M, failing to offset COVID-19 declines. Despite a 40% YoY revenue drop to $1.9B in 2025, MRNA maintains robust liquidity with $8.1B in cash/investments and a conservative 0.151 debt-to-equity ratio.
In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding trading day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior day's close.
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
